Satellite Bio lifts off with $110M
To view this email as a web page, click here

Today's Rundown

Featured Story

AbbVie shreds alpha-synuclein Parkinson's pact on cusp of phase 2, thinning field led by Roche

AbbVie is bowing out of the alpha-synuclein race. Having taken a drug candidate to the cusp of phase 2, AbbVie has terminated its collaboration with BioArctic, leaving a clutch of rivals such as Novartis and Roche to compete over the Parkinson’s disease opportunity.

read more

Top Stories

Arcturus' stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3

How good does a COVID-19 vaccine need to be to muscle in on the market at this late stage of the game? That is the question facing Arcturus as, armed with evidence of 55% efficacy as a primary series, it gears up for booster trials of its self-amplifying COVID-19 mRNA vaccine in the West.

read more

Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapies

Satellite Bio is lifting off with $110 million in new funds, exiting stealth mode after two years to slingshot its implantable tissue therapy into the clinic. CEO Dave Lennon expects this haul to last at least two years as the company expands its platform and prepares one asset for a phase 1 trial.

read more

Sponsored: CDx Biomarkers for Oncology Research & Development

Biomarker discovery and development are critical for advancing oncology therapeutics and informing patient management. Experts discuss evaluating biomarkers in drug-diagnostic co-development programs.

read more

Windtree's phase 2 shock med rapidly raises blood pressure—and share price

Windtree Therapeutics’ cardiogenic shock medicine istaroxime rapidly raised systolic blood pressure in patients with the life-threatening condition, meeting the main goal of a phase 2 study and sending the small biotech’s shares climbing 35% as the markets opened Wednesday.

read more

BioXcel will use $260M finance deal to expand indications for schizophrenia drug

The commercial-stage biopharmaceutical entered a $260 million long-term financing agreement with Oaktree Capital Management and Qatar Investment Authority to accelerate growth and commercially launch a new drug, in return for a share of the profits of any approved therapies.

read more

Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms

Tessera Therapeutics, concocted by life sciences VC staple Flagship Pioneering, topped more than $300 million in its series C round. The haul brings the company's total amount raised to more than $500 million over 15 months—a plethora of capital to grow out every facet of its business as it pushes toward the clinic.

read more

As safety signals mount, FDA aims to crack down on PI3K blood cancer nods

After noticing concerning patient survival data across multiple clinical trials, the FDA is losing confidence in the safety profile of the notoriously toxic PI3K inhibitor drug class for blood cancers. Now, the agency aims to put the meds under a more stringent regulatory scope.

read more

Philips piles on another trio of Class I recalls for beleaguered ventilator portfolio

There seems to be no limit to Philips’ ventilator safety woes. Nearly a full year after initiating a recall of 5.2 million respiratory devices, the company continues to accumulate safety notices for those and other devices in its vast respiratory portfolio.

read more

Groups launch health equity coalition dedicated to chronic disease advocacy

A major purpose of the effort is to avoid duplicating efforts and ensuring all groups’ perspectives and priorities are heard. Its first year, it will focus on obesity.

read more

Abbott's COVID test sales reach all-time high—and probably for the last time, the company says

Diagnostic sales last quarter reached a new high point going back all the way to the start of the pandemic, bringing in more than $3.3 billion worldwide.

read more

AbbVie joins roster of Big Pharmas donating Russian profits as war in Ukraine rages on

This week, AbbVie joined the growing roster of drugmakers that have pledged to donate all Russian profits to Ukrainian relief efforts. The move follows similar vows from Merck & Co., Pfizer, Eli Lilly and GlaxoSmithKline—and it coincides with a renewed philanthropic promise from Swiss pharma Novartis, too.

read more

Digital twin generator Unlearn nets $50M to bolster clinical trials with AI models

The goal is to help drugmakers and academic researchers complete clinical trials while requiring fewer overall participants.

read more

Resources

Research: Healthcare Has No Borders: The Role of Rescue Sites in Times of Global Calamity

More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play?

eBook: 5 Rules to Enhance Wound Care & Dermatology Clinical Trials

Net Health, experts in wound care and dermatology clinical trials, have a new eBook: 5 Rules to Enhance Clinical Trials in 2022, find out how to recruit the right participants, connect patients and researchers with technology, manage costs and more.

Infographic: United Cargo: Providing Comprehensive Solutions For the Most Critical Shipments

The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now.

Research: Get Access to AdisInsight A Year In Review

The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge).

Whitepaper: Oncology Market Outlook: Key Trends to Watch

What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market.

Whitepaper: Uncovering the hidden value of quality in chemical supply

Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific.

Events